Recently, the porous bioactive glasses have attracted a lot of attention for use as scaffolds for tissue engineering bone, such glasses include the high phosphate, strontium containing glass (Stronbone P TM ). However, the previous studies suggest that strontium can have a detrimental effect on the ability of apatite-like phase formation of the glass. The previously studied high phosphate all Sr glass showed an unidentified phase rather than an apatite-like phase upon immersion. Octa-calcium phosphate (OCP) is believed to be a precursor phase to apatite, however octastrontium phosphate does not exist. Fluoride is known to knock out the OCP formation and promotes fluorapatite formation. This work presents the incorporation of a small amount of fluoride into calcium/strontium bioactive glasses. Differential 2 scanning calorimetry was used to estimate the glass thermal properties. All of the studied glass compositions were subjected to bioactivity studies in Tris buffer (pH=7.4) for up to 21 days. The initial glasses and the resultant precipitates were analysed using fourier transform infra red spectroscopy, X-ray diffraction and magic angle spinning-nuclear magnetic resonance. The findings showed that all the fluoride containing glasses were amorphous and there was a marked increase in the rate of apatite formation in vitro compared to the equivalent fluoride free glasses, particularly for the all strontium containing glass. This indicates that the presence of fluoride affects the pathway of apatite formation, forming fluorapatite directly instead of via the transformation from OCP to hydroxyapatite. Therefore, fluoride may have potential future clinical applications as an additive to increase apatite formation.
Introduction
There is considerable interest in developing porous bioactive glasses for the use as scaffolds for tissue engineering bone. A glass suitable for the use as a scaffold should fulfill the following criteria:
1. It should be capable of being sintered by a viscous flow mechanism without crystallisation to give a three dimensional open porous structure with an interconnect size of at least 100 microns to facilitate infiltration by both blood vessels and osteoblasts.
2. It should form an apatite-like layer on its surface.
3. It should not result in a too high pH rise in vivo. 4 . It should actively stimulate the formation of new bone tissue and should osseointegrate.
It should promote angiogenesis.
The strontium containing bioactive glass (SP-Ca/Sr, Stonbone P TM ) given in Table 1 exhibits these properties and shows rapid osseointegration and new bone formation in vivo (1) . Strontium is known to up-regulate osteoblasts and down-regulate osteoclasts (2) . Strontium is also slightly bactericidal (3) (4) and also of relatively high atomic number enabling the placement and resorption of strontium based biomaterials to be visualised using standard X-ray methods. Silicon released from bioactive glass has been shown to stimulate angiogenesis (3) . Glass SP-Ca/Sr exhibits a large processing window defined as the onset temperature of crystallisation minus the glass transition temperature (T conset -T g ). This large processing window of over 200 o C enables the glass particles to be viscous flow sintered without crystallisation occurring. This enables the glass to be formed into porous structures by a variety of routes. The low alkali metal content and high phosphate content reduces the pH rise, whilst the high phosphate content is known to increase the amount of apatite formed and reduce the time to form apatite (5) (6).
However, Sriranganathan et al. (7) found that the introduction of strontium has a detrimental effect on the apatite-like phase formation ability of the glasses.
Sriranganathan et al. investigated the in vitro bioactivity of the glass given in Table 1 and the equivalent glasses containing only calcium and no strontium and only strontium and no calcium (7) . The all strontium high phosphate bioactive glass showed the glass to form a new unidentified phase upon immersion in Tris buffer.
This new phase is not a strontium apatite (Sr 10 (PO 4 ) 6 F 2 ) or Collins salt (Sr 6 H 3 (PO 4 ) 5 ·2H 2 O) and has not been found previously. This phase seems to be a strontium orthophosphate, based on FTIR and 31 P MAS-NMR data. We have termed this new unidentified phase as "X-phase". In contrast, the related calcium containing glass and mixed calcium/strontium glass form an apatite-like phase in both Tris buffer and simulated body fluid. The all strontium glass also forms an apatite-like phase in SBF though its identification is far from conclusive. It is thought that apatite formation goes via the formation of an octa-calcium phosphate precursor phase (Ca 8 (PO 4 ) 6 H 2 .5H 2 O) if the pH <9 (8) (9) . However, octa-strontium phosphate (Sr 8 (PO 4 ) 6 H 2 .5H 2 O) does not exist (7) . Consequently with the strontium bioactive glass it is thought that because the precursor phase can not form, that the formation of an apatite phase is not possible and the X-phase forms instead. In SBF, which contains calcium ions, the strontium containing glass degraded and resulted in octacalcium phosphate formation with possibly a small amount of strontium substituted for calcium in the octa-calcium phosphate lattice. Fluoride is known to knock out the OCP precursor phase and form an apatite directly (10). Brauer et al. (11) and Mneimne et al. (12) showed that fluoride containing bioactive glasses formed fluorapatite and that apatite formation was enhanced by the presence of fluoride.
Their results (11) (12) can be explained by fluoride knocking out the precursor OCP phase and forming an apatite directly. The fluoride ion is smaller than hydroxyl ion and therefore the fluoride ion can fit into the space at the center of the Ca(II) triangle in the apatite crystal lattice and form a more stable fluorapatite compared with hydroxyapatite. There is little direct conclusive evidence for OCP formation with bioactive glasses. This is in part due to OCP and hydroxyapatite being very difficult to distinguish by fourier transform infrared spectroscopy or X-ray powder diffraction.
OCP exhibits one characteristic diffraction line at 4.68 o two theta with copper K-α Xrays. Most studies in the literature do not access this very low two theta range.
Furthermore OCP transforms readily to hydroxycarbonated apatite and the 4.68 o two theta spacing corresponds to the large >2nm water layer which is very prone to structural disorder and Scherrer line broadening. Fluoride is also known to knock out the formation of Collin's salt and also cause the direct formation of apatite (10) .
Fluoride has been shown to not only knock out OCP as a precursor phase to apatite, but also inhibits the formation of Collin's salt from strontium and phosphate containing solutions at pH=7.0, resulting in direct formation of a strontium fluoridated apatite (13). Feenstra et al. (13) also found that the fluoridated apatite formed exhibited very strong heterogenous nucleation and its formation exhibited a maximum with fluoride concentration in solution.
Apart from promoting rapid fluorapatite formation, it is also shown that fluoride regulates bone-forming cell activities, promotes osteoblasts-like cell pre-osteogenic, pro-angiogenic responses and bone resorption in vitro (14) (15) . Moreover, it is also found that fluoride enables to stimulate osteoblast mitosis and bone formation (16) .
Those benefits are favourable in the applications of bone substitutes.
Based on these factors it was chosen to investigate bioactive glasses with small fluoride additions and evaluate their degradation and apatite formation abilities in Tris buffer. The hypothesis being that fluoride release from the bioactive glasses will prevent the formation of OCP and other phases like the Collin's salt, the X-phase and form a fluoridated apatite directly, competing with the normal hydroxyapatite formation pathway (17) .
Materials and Methods
The studied glasses were produced by a melt-quenched method in a similar way to a previous paper published by this research group, Sriranganathan et al. (7) . The relevant oxides and fluorides were mixed and melted at the appropriate firing temperature shown in Table 1 for 1 hour in a platinum crucible. Different temperatures were used to account for the contrasting effects of strontium and fluorine on the melting temperature of the glasses (18) . After 1 hour melting, deionised water was used to quench the glass and the resultant coarse powder glass was collected, dried overnight and ground into powder using a Gy-Ro Mill (Glen Creston Ltd, Twickenham UK). An Endecotts EFL 2000/1 automated sieve shaker was used to separate the powder into a fine (<38 µm) and coarse powder. A Stanton Redcroft DSC 1500 (Rheometric Scientific, Epsom, UK) was then used to analyse the fine and coarse powder to determine the glass transition temperature (T g ), crystallisation onset temperature (T conset) , processing window (defined as T conset -T g ) and crystallisation peak termperature (T c ) with an accuracy of ±5 °C. The acellular 'bioactivity' test was conducted at 37°C in an incubator with a rotational speed of 60rpm, using 150mg fine glass powder incubated for periods of 1, 3, 7, 14 and 21days in 100ml of Tris buffer solution (19) . After the various time intervals XRD and FTIR experiments were carried out as previously described (20) The spectra were recorded after 560 scans and 60 seconds relaxation. Sodium fluoride 1M aqueous solution producing a sharp signal at -120 ppm was used as a secondary reference against CFCl 3 .
Results and Discussion
All the glasses were optically clear and amorphous by XRD (Figure 1 ). The maximum in the amorphous scattering shifted to lower two theta values with increasing strontium content as found previously for a number of bioactive glass series where strontium has been substituted for calcium (21) M is largely Ca/Sr and Na. Brauer et al. (28) showed that F was complexed by Ca and Na with mixed F-Ca/Na(n) species present, whilst Chen et al. (29) showed that F-Ca(n) species were present in sodium-free fluoride containing glasses. It is clear that the spectra move to a higher chemical shift with increasing Sr content. The all Ca glass exhibits a peak at about -100 ppm while the all Sr glass one at -83.2 ppm and the mixed one sits in between. This is due to the fact that Sr In this glass it appears as if 2 mol% CaF 2 is sufficient to inhibit the formation of the X phase and promote the formation of fluorapatite. This is significant as the retardation of apatite formation caused by a high concentration of strontium is a limiting factor in its use in commercial bioactive glass formulations. Based on this in vitro study in Tris, fluoride is found to act independently of strontium to increase apatite formation.
Although, the presence of fluoride also has some undesirable effects such as reducing the size of the sintering window, which will impede sintering and the synthesis of amorphous porous scaffolds. However, the sintering window is still over 100 °C.
It is important to note that in vivo there will always be a continuous turnover of calcium rich body fluids and a readily available supply of calcium ions, which will favour apatite formation. This effect is not included in the present study nor is it included in the widely used Simulated Body Fluid test developed by Kokubo.
Conclusion
The incorporation of fluoride leads to a reduction in T g , T c and the sintering window.
In this in vitro study small additions of fluoride act independently to increase apatite formation with both strontium free and strontium containing bioactive glasses, counteracting the negative effects that strontium has on apatite formation. The effect of fluoride is most pronounced in the all strontium glass, which formed a strontium fluorapatite. The fact that fluoride promotes apatite formation in all the glasses and especially the all strontium one supports the hypothesis that apatite formation occurs via an OCP precursor phase in bioactive glasses and that strontium suppresses the formation of apatite, since octa-strontium phosphate cannot form. Moreover, the incorporation of fluoride knocks out the formation of OCP and results in the direct formation of fluorapatite. As a consequence of this, fluoride can be used as a promising additive to increase the apatite formation with bioactive glasses for tissue engineered scaffolds and this is particularly beneficial where it is undesirable for the pH to increase to high values.
